The Annual General Meeting of Pharmexa A/S was held on Monday March 31st 2008
at 4:00 pm.
The annual report was approved and the board of directors and the management
was given discharge.
The board of directors' proposal to distribution of the profit or settlement of
loss was approved.
Proposal from the board of management concerning approval of general guidelines
for the incentive program of the board of management was approved.
The proposed changes of article 13.1 of the articles of association were
approved.
The board members were re-elected. After the meeting the board constituted
itself with Ole Steen Andersen as the chairman.
Ernst & Young was re-elected as state authorised accountants.
Hørsholm, April 1, 2008
Jakob Schmidt
Chief Executive Officer
Additional information:
Jakob Schmidt, CEO, tel +45 4516 2525
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45
4516 2525 or +45 4060 2558
For the editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, GENimmune, IDM Pharma, Bavarian
Nordic and Ichor Medical Systems. With operations in Denmark, Norway and USA,
Pharmexa employs approximately 80 employees and is listed on the Copenhagen
Stock Exchange under the trading symbol PHARMX.
